Russell Howard - Prima Biomed Non-Executive Director

Director

Dr. Russell John Howard, Ph.D., serves as NonExecutive Director of Prima Biomed Ltd since 2013.
Age 64
Tenure 11 years
Professional MarksPh.D
Phone61 2 8315 7003
Webhttp://www.primabiomed.com.au
Russell is an Australian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of “DNA Shuffling”. He is an inventor of 9 patents and has over 150 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr. Howard worked at ScheringPlough’s DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and cofounder and CEO of Maxygen, Inc. After its spinout from GlaxoWellcome. As Maxygen’s CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260 million. Maxygen developed and partnered dozens of technology applications and products. After leaving Maxygen in 2008, he started the Cleantech company Oakbio, Inc. And remains involved in several innovative companies in the USA and Australia

Prima Biomed Management Efficiency

The company has return on total asset (ROA) of (15.25) % which means that it has lost $15.25 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (30.29) %, meaning that it created substantial loss on money invested by shareholders. Prima Biomed's management efficiency ratios could be used to measure how well Prima Biomed manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 4.6 M in liabilities with Debt to Equity (D/E) ratio of 21.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Prima Biomed has a current ratio of 5.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Prima Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, Prima Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prima Biomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prima to invest in growth at high rates of return. When we think about Prima Biomed's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Bradley BussTesla Inc
54
Greg MaxwellJeld Wen Holding
63
Estelle MetayerUbisoft Entertainment
46
Christian GuillemotUbisoft Entertainment
57
Anthony MunkJeld Wen Holding
59
Robyn DenholmTesla Inc
54
Patrick TolbertJeld Wen Holding
71
Stephen JurvetsonTesla Inc
51
Michel GuillemotUbisoft Entertainment
64
Wilton IngramIntegrated Media Technology
N/A
Girish RishiDigi International
46
Antonio GraciasTesla Inc
47
Christopher HeimDigi International
53
Frederique DameUbisoft Entertainment
42
Martha ByorumJeld Wen Holding
70
Pascale MounierUbisoft Entertainment
52
James MurdochTesla Inc
45
Suzanne StefanyJeld Wen Holding
57
Steven WynneJeld Wen Holding
68
Chris HeimDigi International
N/A
Guy JacksonDigi International
72
Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology solutions in Australia. Prima Biomed (PBMD) is traded on NASDAQ Exchange in USA and employs 31 people.

Management Performance

Prima Biomed Leadership Team

Elected by the shareholders, the Prima Biomed's board of directors comprises two types of representatives: Prima Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prima. The board's role is to monitor Prima Biomed's management team and ensure that shareholders' interests are well served. Prima Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prima Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pete Meyers, Non-Executive Director
Russell Howard, Non-Executive Director
Larisa Chisholm, Director of Industry Liaison and Devel. and Director of Intellectual Property
Tom Bloomfield, Joint Company Secretary
YueLing Wong, Non-Executive Deputy Chairman of the Board
Frederic Triebel, Chief Scientific Officer & Chief Medical Officer
Deanne Miller, General Counsel, Company Secretary
Sharron Gargosky, Chief Technical Officer
Grant Chamberlain, Non-Executive Director
Lucy Turnbull, Non-Executive Chairman of the Board
Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee
Matthew Gregorowski, IR Contact Officer

Prima Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prima Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Prima Biomed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Prima Biomed's short interest history, or implied volatility extrapolated from Prima Biomed options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Prima Biomed using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Prima Stock

If you are still planning to invest in Prima Biomed check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prima Biomed's history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA